ZLAB News and Press, Zai Lab Limited From 08/07/23

2023-08-07 16:42:20 ET Zai Lab press release ( NASDAQ: ZLAB ): Q2 GAAP EPS of -$1.25 misses by $0.50 . Revenue of $68.86M (+43.0% Y/Y) misses by $1.81M . For further details see: Zai Lab GAAP EPS of -$1.25 misses by $0.50, revenue of $68.86M misses by $1.81M

Total product revenue of $68.9 million for the second quarter of 2023, representing 45% y-o-y growth; 53% y-o-y growth at constant exchange rate VYVGART ® (efgartigimod alfa injection) approved in China as first-and-only neonatal Fc receptor (FcRn) blocker for general...

2023-08-03 11:40:42 ET Summary On August 2, Blueprint Medicines, a pharmaceutical company developing medicines for treating cancer and blood diseases, released its financial results for the second quarter of 2023. Blueprint Medicines' revenue for the second quarter of 2023 was $57...

2023-07-26 23:36:47 ET Summary Zai Lab Limited's recent clinical study results and partnerships demonstrate its commitment to innovation and product development, positioning it as a strong investment prospect in the pharmaceutical industry. The company's partnership with MediLink ...

SHANGHAI, China and CAMBRIDGE, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the second quarter of 2023 and recent corporate updates, after the closing of the U.S. equity markets on August 7, 2023. The...

The Phase 3 PRIME study demonstrates that treatment with ZEJULA significantly extends progression-free survival versus placebo and reduces the risk of disease progression or death by 55% Findings confirm the benefit of ZEJULA monotherapy as first-line maintenance treatment, regardle...

Study met primary endpoint (p=0.000039); VYVGART ® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG autoantibodies shown to play significant role in underlying CIDP disease biology Favorable safety and tolerability pro...

SHANGHAI, China and CAMBRIDGE, Mass., July 14, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been treated in the mainland China portion of the global registrational, Phase 3 FORTITUDE-101 study for bemarituzumab, a potential first-i...

2023-07-12 15:34:17 ET Summary Zai Lab's Q1 2023 earnings show a significant growth in product revenues, a decrease in R&D expenses, and a decrease in net loss compared to 2022. Despite underperforming compared to the S&P 500, Zai Lab's earnings projections suggest substan...

SHANGHAI, China and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for efgartigimod alfa injection (subcutaneous...